Saturday, February 25, 2023 11:57:22 AM
Jack,
Thanks for your opinion, but I think LP has a track record of solid business acumen and integrity. She is also holding a lot of shares.
The CEO of Northwest Biotherapeutics has worked for the U.S. government, was the managing director of a capital fund, and is a Harvard lawyer, so I am sure that she understands how to navigate these waters.
Her experience includes a presidential appointment to the U.S. Commerce Department many years ago. She also taught a course at the U.S. National Institutes of Health on the development and commercialization of medical products.
https://www.c-span.org/video/?c5017932/user-clip-linda-powers-testifying-congress
NIH Support:
LP’s background:
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/
Thanks for your opinion, but I think LP has a track record of solid business acumen and integrity. She is also holding a lot of shares.
The CEO of Northwest Biotherapeutics has worked for the U.S. government, was the managing director of a capital fund, and is a Harvard lawyer, so I am sure that she understands how to navigate these waters.
Her experience includes a presidential appointment to the U.S. Commerce Department many years ago. She also taught a course at the U.S. National Institutes of Health on the development and commercialization of medical products.
https://www.c-span.org/video/?c5017932/user-clip-linda-powers-testifying-congress
NIH Support:
LP’s background:
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
